Swedish council warns against AI tools in cancer care
Published
The Swedish Product Council for Medical Technology has recommended that the regions not use Stratipath's AI tool to make treatment decisions for a group of patients. The tool is used to analyse tissue samples from patients with cancer and is meant to help doctors judge which treatment may suit best.
Stratipath, a company that originates from Sweden, is not happy with the council's assessment. The company says the conclusions are wrong and that they are not true at all. According to the company, the tool is based on scientific research, and it believes the council's picture of the studies is misleading.
The issue is important for patients and healthcare staff in Sweden, because the regions themselves decide which methods and tools are used in healthcare. The council gives recommendations, but the decision on use lies with each region. It is still unclear how the regions will act after the council's statement.
The debate shows how difficult it can be to introduce new AI-based tools in health and medical care. While the technology can give faster and more precise analyses, it must be checked carefully before it is used in patient treatment. Both authorities and companies are expected to continue the discussion in the coming months.
Sources: www.lifesciencefocus.com
More Sweden news
- Slow start for Sverige-id: authorities can get up to nine months' exemption
- Marcus Bergman leaves Sweden after more than 400 matches in Hockeyallsvenskan
- Trust in Sweden could affect the country's defence capability
- Danish drugmaker LEO Pharma postpones its stock market listing
- New rabies vaccine from Sanofi approved in the EU
- This is what the Swedish royals are really like, according to an expert
- Musikhjälpen 2026: The first prize is tickets to a Premier League match
- Business leaders impatient with AI: small progress is no longer enough